These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11442886)

  • 1. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
    Ishigooka J; Murasaki M; Miura S;
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):353-63. PubMed ID: 11442886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
    Ishigooka J; Murasaki M; Miura S
    Psychiatry Clin Neurosci; 2000 Aug; 54(4):467-78. PubMed ID: 10997865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J; Inada T; Miura S
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events related to olanzapine.
    Conley RR; Meltzer HY
    J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of olanzapine.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():13-7. PubMed ID: 9265911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
    Costa e Silva JA; Alvarez N; Mazzotti G; Gattaz WF; Ospina J; Larach V; Starkstein S; Oliva D; Cousins L; Tohen M; Taylor CC; Wang J; Tran PV
    J Clin Psychopharmacol; 2001 Aug; 21(4):375-81. PubMed ID: 11476121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.
    Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV
    J Clin Psychiatry; 2002 Jul; 63(7):569-76. PubMed ID: 12143912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
    Ross RG; Novins D; Farley GK; Adler LE
    J Child Adolesc Psychopharmacol; 2003; 13(3):301-9. PubMed ID: 14642018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
    Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
    Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    Jones B; Taylor CC; Meehan K
    J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe akathisia during olanzapine treatment of acute schizophrenia.
    Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C
    Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
    J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.